What is Kymera Therapeutics's net investment in lease?

Kymera Therapeutics (KYMR) reported net investment in lease of $41.74M in Q1 2026.

How has Kymera Therapeutics's net investment in lease changed year-over-year?

Kymera Therapeutics's net investment in lease decreased by 10.7% year-over-year, from $46.73M to $41.74M.

What is the long-term trend for Kymera Therapeutics's net investment in lease?

Over 5 years (2020 to 2025), Kymera Therapeutics's net investment in lease has grown at a 33.9% compound annual growth rate (CAGR), from $9.85M to $42.35M.

Kymera Therapeutics KYMR Net Investment in Lease

Net Investment in Lease at other companies

ImmunityBio, Inc.IBRX

——

Krystal Biotech, Inc.KRYS

——

Protagonist TherapeuticsPTGX

——

Apogee Therapeutics, Inc.APGE

——

TG TherapeuticsTGTX

——

InsmedINSM

——

Other financials

Income statement

See full

Revenue$34.4M+55.5%

Operating income-$84.2M-13.1%

Net income-$69.2M-5.6%

EPS (diluted)-$0.71+13.4%

Balance sheet

See full

Cash & equivalents$144.1M+60.2%

Total debt$82.2M-6.5%

Total equity$1.5B+95.8%

Total assets$1.7B+81.7%

Cash flow

See full

Operating cash flow-$88.8M-12.2%

CapEx$434.0K-7.1%

Free cash flow-$89.3M-12.1%

Valuation

See full

Market cap$7.44B+283%

Enterprise value$7.38B+280%

P/S144.5×+111×

Profitability

See full

Operating margin-697.7%+635pp

Net margin-612%+602pp

FCF margin-474%+92.4pp

Returns & leverage

See full

Return on equity-27.1%-3.7pp

Debt / equity0.1×-0.1×

Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kymera Therapeutics's net investment in lease?: Kymera Therapeutics (KYMR) reported net investment in lease of $41.74M in Q1 2026.
How has Kymera Therapeutics's net investment in lease changed year-over-year?: Kymera Therapeutics's net investment in lease decreased by 10.7% year-over-year, from $46.73M to $41.74M.
What is the long-term trend for Kymera Therapeutics's net investment in lease?: Over 5 years (2020 to 2025), Kymera Therapeutics's net investment in lease has grown at a 33.9% compound annual growth rate (CAGR), from $9.85M to $42.35M.